<DOC>
	<DOCNO>NCT00101920</DOCNO>
	<brief_summary>Rationale : Overexpression epidermal growth factor receptor ( EGFR ) observe kidney , prostate , colon , lung , breast , cancer , often associate poor prognosis . TGFa EGF , ligands EGFR , also overexpressed tumor type , suggest self-propagating stimulus may responsible rapid tumor growth . Blocking stimulus block activation EGFR ABX-EGF , fully human monoclonal antibody EGFR , may prevent tumor growth perhaps shrink tumor . Purpose : This Phase 2 clinical trial evaluate safety efficacy ABX-EGF treatment advance NSCLC follow failure paclitaxel carboplatin therapy treatment arm 1 Immunex Protocol 054.0004 ( Amgen Protocol 20025404 ) , Part 2 .</brief_summary>
	<brief_title>ABX-EGF Second Line Treatment Advanced Non-Small-Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>18 year age old . Diagnosis NSCLC . Unidimensionally measurable disease . Documented disease progression within 6 month subject 's last dose carboplatin paclitaxel treatment arm 1 , part 2 Immunex Protocol 054.0004 ( Amgen Protocol 20025404 ) . Disease stage IIIB pericardial pleural effusion , stage IV . Life expectancy least 12 week . ANC great equal 1.5 x 10^9/L , platelet count great equal 100 x 10^9/L . Adequate hematology function Adequate renal function Adequate hepatic function ECOG score less 2 . Brain metastasis , present , must control asymptomatic . Calcium &gt; ULN ( treatment hypercalcemia allow ) . Use investigational therapy within 30 day ABXEGF infusion . Any cancer therapy NSCLC paclitaxel carboplatin per Immunex Protocol 054.0004 ( Amgen Protocol 20025404 ) , radiation therapy , surgery , steroid . Paclitaxel carboplatin within 30 day first ABXEGF infusion . Radiation therapy within 2 week ABXEGF infusion . LVEF le 45 % measure MUGA . Symptomatic ventricular arrhythmia symptomatic conduction abnormality . Myocardial infarction within 1 year first dose study drug . History cancer require treatment active within past 5 year , NSCLC , basal cell carcinoma , cervical carcinoma situ . Women ( e.g. , childbearing potential , postmenopausal less six month , surgically sterilize abstinent ) willing use oral implanted contraceptive , double barrier birth control , IUD course study 6 month follow treatment . Men willing use contraception upon enrollment study 1 month follow treatment . Women breastfeed positive pregnancy test within 72 hour first study drug administration . Known HIV positive . Any patient 's best medical interest would meet entry study opinion Investigators .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>